(Q36561637)

14 August 2017

1 reference

title

Shifting emphasis from pharmacogenomics to theragnostics (English)

1 reference

14 August 2017

1 reference

2

Bryn Williams-Jones

0 references

Stephen J Glatt

object named as

Stephen J Glatt

3

0 references

Vural Özdemir

1

object named as

Vural Ozdemir

1 reference

14 August 2017

Ming T Tsuang

4

1 reference

14 August 2017

James B Lohr

5

1 reference

14 August 2017

Christopher Reist

6

1 reference

14 August 2017

publication date

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

942-946

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt0806-942

14 August 2017

exact match

0 references

cites work

Rhetoric and hype: where's the 'ethics' in pharmacogenomics?

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

The myth of the biotech revolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Knowledge commons or economic engine--what's a university for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

The complexities of predictive genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Diagnostic testing fails the test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

SARS genome patent: symptom or disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Decoding the research exemption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Excess in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

Geneticists question fees for use of patented 'junk' DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

The drugs don't work: expectations and the shaping of pharmacogenetics

21 January 2018

1 reference

12 December 2020

Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations

1 reference

12 December 2020

Genset-Abbott deal heralds pharmacogenomics era

1 reference

12 December 2020

Molecular diagnostics and personalized medicine. IBC Life Sciences Conference on Pharmacogenomics, June 24-25, 2003, London, UK

1 reference

12 December 2020

Treatment research at the millennium: from efficacy to effectiveness

1 reference

12 December 2020

Designer drugs. What's best for patients isn't always what's best for profits

1 reference

12 December 2020

Patenting and human genes

1 reference

12 December 2020

Surviving the blockbuster syndrome

1 reference

12 December 2020

NCI-Myriad agreement offers BRCA testing at reduced cost

1 reference

12 December 2020

Will pharmacogenomics alter the role of patents in drug development?

1 reference

12 December 2020

Policy conflicts: gene patents and health care in Canada

1 reference

12 December 2020

Don't mention the war..

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-942

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NBT0806-942

1 reference

Dimensions Publication ID

14 August 2017

1032133391

0 references

1 reference